Prosecution Insights
Last updated: April 19, 2026
Application No. 18/023,270

COMPOUNDS AND METHODS OF USE

Non-Final OA §112
Filed
Feb 24, 2023
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ferro Therapeutics Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 10, 13, 20-22, 24, 27-28, 32-35, 39, 43, 54, and 58 are pending. Claims 13, 20-21, 24, 33-35, 39, 43, and 58 are withdrawn. Claims 1 and 54 are rejected. Claim 32 is allowable. Claims 10, 22, and 27-28 are objected to. Information Disclosure Statement The Information Disclosure Statement (IDS) submitted on 2/24/2023 was considered by the Examiner. Election/Restrictions Applicant’s election without traverse of Group I and the species A-16: PNG media_image1.png 134 168 media_image1.png Greyscale ** in the reply filed on 2/2/2026 is acknowledged. **Applicant originally elected a species that was excluded from claim 1. Examiner contacted Applicant and they changed their election to compound A-16, shown supra, on 2/21/2026. Claims 1, 10, 22, 27-28, 32 and 54 embrace the elected species and are therefore under examination. Applicant’s elected species is allowable. As per MPEP 803.02, “Following election, the Markush claim will be examined fully with respect to the elected species and further to the extent necessary to determine patentability.” Additionally, claim 32 has been searched in full and is allowable. Claims 1, 10, 22, 27-28 and 54 are free of the art but have been rejected/objected to below in the interest of compact prosecution. Claims 13, 20-21, 24, 33-35, 39, 43, and 58 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Objections Claim 1 is objected to because of the following informalities: For the compounds listed on p. 5-8, Examiner recommends placing commas between them and inserting an “or” between the last two; Claim 1 does not end in a period. Appropriate correction is required. Additionally, claims 10, 22, 27-28 and 54 are objected to for depending from an objected claim and failing to remedy the deficiencies. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 54 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. On p. 8 of claim 1, the last two compounds: PNG media_image2.png 127 448 media_image2.png Greyscale , do not correctly depend from instant formula A-1: PNG media_image3.png 164 298 media_image3.png Greyscale (all within the same claim), particularly the cyclic “A” requirement. It is unclear if the cyclic “A” is truly required or not, because of this discrepancy. If cyclic “A” is required, Examiner recommends removing the last two compounds, shown supra, from the list on p. 8. Claims 10, 22, and 27-28, which depend from claim 1, either directly or indirectly require the cyclic “A”. Claim 54 is rejected for depending from claim 1 and failing to remedy its deficiencies. Closest Prior Art The closest prior art is US11040964 (eligible as 102(a)(2) art). US11040964 teaches the following compound as an intermediate in column 129: PNG media_image4.png 225 287 media_image4.png Greyscale . This compound is excluded from the instant claims on p. 5, bottom line. As an intermediate in the prior art and specifically excluded from the instant claims, this prior art compound does not provide motivation for, nor render obvious, the instant claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/ Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 24, 2023
Application Filed
Feb 21, 2026
Examiner Interview (Telephonic)
Feb 23, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month